Usa India covid-19 2020 vaccine Usa India

Cadila’s Q2 results impressive as investors bank on covid-19 drugs to deliver

Reading now: 924
www.livemint.com

revenues grew a decent 13% year-on-year (y-o-y). Its stock gained about 8% on the better-than-expected Q2 performance.Cadila’s divisions have all perked up nicely with US growing at about 18% y-o-y.

The India business growth of 11% is good given that the acute segment is not firing that well. The increased demand for active pharma ingredients (API) also pushed revenues in this division higher by about 52%.In the coming quarters, investors are banking on the increased contribution from the covid-19 portfolio.

The firm is working on a covid-19 vaccine with immunogenicity and efficacy data likely to be out soon. Besides, backward integration in API manufacturing is aiding margins in its covid-19 portfolio.“Cadila has launched the most.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA